
FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL
The FDA issued a complete response letter (CRL) for the supplemental biologics license application (sBLA) for glofitamab-gxbm (Columvi; Genentech) in combination with gemcitabine (Gemzar; Eli Lilly and Co) and oxaliplatin (GemOx, Eloxatin; Sanofi) for the …